149 related articles for article (PubMed ID: 14593713)
1. Phospholipase D and choline kinase: their role in cancer development and their potential as drug targets.
Rodríguez-González A; Ramírez de Molina A; Benítez-Rajal J; Lacal JC
Prog Cell Cycle Res; 2003; 5():191-201. PubMed ID: 14593713
[TBL] [Abstract][Full Text] [Related]
2. Choline kinase: a novel target for antitumor drugs.
Lacal JC
IDrugs; 2001 Apr; 4(4):419-26. PubMed ID: 16015482
[TBL] [Abstract][Full Text] [Related]
3. Choline kinase as a link connecting phospholipid metabolism and cell cycle regulation: implications in cancer therapy.
Ramírez de Molina A; Gallego-Ortega D; Sarmentero-Estrada J; Lagares D; Gómez Del Pulgar T; Bandrés E; García-Foncillas J; Lacal JC
Int J Biochem Cell Biol; 2008; 40(9):1753-63. PubMed ID: 18296102
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of ChoK is an efficient antitumor strategy for Harvey-, Kirsten-, and N-ras-transformed cells.
Ramírez de Molina A; Rodríguez-González A; Penalva V; Lucas L; Lacal JC
Biochem Biophys Res Commun; 2001 Jul; 285(4):873-9. PubMed ID: 11467831
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells.
Rodríguez-González A; Ramírez de Molina A; Fernández F; Ramos MA; del Carmen Núñez M; Campos J; Lacal JC
Oncogene; 2003 Dec; 22(55):8803-12. PubMed ID: 14654777
[TBL] [Abstract][Full Text] [Related]
6. Choline kinase inhibitors as a novel approach for antiproliferative drug design.
Hernández-Alcoceba R; Saniger L; Campos J; Núñez MC; Khaless F; Gallo MA; Espinosa A; Lacal JC
Oncogene; 1997 Nov; 15(19):2289-301. PubMed ID: 9393874
[TBL] [Abstract][Full Text] [Related]
7. Proteomic approaches for the identification of cell cycle-related drug targets.
Flory MR; Aebersold R
Prog Cell Cycle Res; 2003; 5():167-71. PubMed ID: 14593710
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
[TBL] [Abstract][Full Text] [Related]
9. Cell signaling and cancer-possible targets for therapy.
Wenner CE
J Cell Physiol; 2010 May; 223(2):299-308. PubMed ID: 20127706
[TBL] [Abstract][Full Text] [Related]
10. Tailoring Ras-pathway--inhibitor combinations for cancer therapy.
Blum R; Kloog Y
Drug Resist Updat; 2005 Dec; 8(6):369-80. PubMed ID: 16356760
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity of normal, paramalignant, and malignant human urothelial cells to inhibitors of the epidermal growth factor receptor signaling pathway.
MacLaine NJ; Wood MD; Holder JC; Rees RW; Southgate J
Mol Cancer Res; 2008 Jan; 6(1):53-63. PubMed ID: 18234962
[TBL] [Abstract][Full Text] [Related]
12. From Ras signalling to ChoK inhibitors: a further advance in anticancer drug design.
Ramírez de Molina A; Rodríguez-González A; Lacal JC
Cancer Lett; 2004 Apr; 206(2):137-48. PubMed ID: 15013519
[TBL] [Abstract][Full Text] [Related]
13. Mining the NCI screening database: explorations of agents involved in cell cycle regulation.
Wallqvist A; Monks A; Rabow AA; Thanki N; Shoemaker RH; Covell DG
Prog Cell Cycle Res; 2003; 5():173-9. PubMed ID: 14593711
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological inhibitors of the ERK signaling pathway: application as anticancer drugs.
Kohno M; Pouyssegur J
Prog Cell Cycle Res; 2003; 5():219-24. PubMed ID: 14593716
[TBL] [Abstract][Full Text] [Related]
15. [Regulation of the cell cycle and the development of cancer: therapeutic prospects].
Peralta-Zaragoza O; Bahena-Román M; Díaz-Benítez CE; Madrid-Marina V
Salud Publica Mex; 1997; 39(5):451-62. PubMed ID: 9424727
[TBL] [Abstract][Full Text] [Related]
16. The contemporary drug development process: advances and challenges in preclinical and clinical development.
Garrett MD; Walton MI; McDonald E; Judson I; Workman P
Prog Cell Cycle Res; 2003; 5():145-58. PubMed ID: 14593708
[TBL] [Abstract][Full Text] [Related]
17. Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis.
Ramírez de Molina A; Gallego-Ortega D; Sarmentero J; Bañez-Coronel M; Martín-Cantalejo Y; Lacal JC
Cancer Res; 2005 Jul; 65(13):5647-53. PubMed ID: 15994937
[TBL] [Abstract][Full Text] [Related]
18. Choline kinase activation is a critical requirement for the proliferation of primary human mammary epithelial cells and breast tumor progression.
Ramírez de Molina A; Báñez-Coronel M; Gutiérrez R; Rodríguez-González A; Olmeda D; Megías D; Lacal JC
Cancer Res; 2004 Sep; 64(18):6732-9. PubMed ID: 15374991
[TBL] [Abstract][Full Text] [Related]
19. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
Gollob JA; Wilhelm S; Carter C; Kelley SL
Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
[TBL] [Abstract][Full Text] [Related]
20. [Methyl-3H]-choline incorporation into MCF-7 cells: correlation with proliferation, choline kinase and phospholipase D assay.
Al-Saeedi F; Smith T; Welch A
Anticancer Res; 2007; 27(2):901-6. PubMed ID: 17465218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]